Company

Solu Therapeutics, Inc.

Solu Therapeutics develops medicines designed to eliminate cells that cause disease.

About

Solu Therapeutics uses its CyTaC platform to develop therapies targeting disease-causing cells, including those involved in cancer, immunology, and autoimmunity. Founded in 2023 by David Donabedian and Brandon Turunen, the company is based in Massachusetts, US. In April 2025, it raised USD 41 million in Series A funding from Eli Lilly & Company, Biovision Ventures, Pappas Capital, and The Leukemia & Lymphoma Society, with participation from Longwood Fund, Data Collective, Sante Ventures, Astellas Venture Management, and Alexandria Venture Investments.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in